Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Distribution of angiographic measures of restenosis after drug-eluting stent implantation.

Byrne RA, Eberle S, Kastrati A, Dibra A, Ndrepepa G, Iijima R, Mehilli J, Schömig A.

Heart. 2009 Oct;95(19):1572-8. doi: 10.1136/hrt.2008.161398. Epub 2009 May 28.

PMID:
19482849
2.

Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.

Xu B, Yang Y, Yuan Z, Du Z, Wong SC, Généreux P, Lu S; RESOLUTE China RCT Investigators.

JACC Cardiovasc Interv. 2013 Jul;6(7):664-70. doi: 10.1016/j.jcin.2013.03.001. Epub 2013 Mar 21.

3.

One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.

Chevalier B, Moulichon R, Teiger E, Brunel P, Metzger JP, Pansieri M, Carrie D, Stoll HP, Wittebols K, Spaulding C, Fajadet J; Cristal Investigators.

J Interv Cardiol. 2012 Dec;25(6):586-95. doi: 10.1111/j.1540-8183.2012.00769.x. Epub 2012 Sep 20.

PMID:
22994863
4.

Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.

Markovic S, Paliskyte R, Rottbauer W, Wöhrle J.

Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):307-10. doi: 10.1016/j.carrev.2012.09.003.

PMID:
23164475
5.

Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.

Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati A; ISAR-DESIRE 2 Investigators.

J Am Coll Cardiol. 2010 Jun 15;55(24):2710-6. doi: 10.1016/j.jacc.2010.02.009. Epub 2010 Mar 11.

6.
7.

Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer.

Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schömig A, Kastrati A.

JACC Cardiovasc Interv. 2009 Apr;2(4):291-9. doi: 10.1016/j.jcin.2008.11.015.

8.

2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.

Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schömig A, Mehilli J; ISAR-TEST-2 Investigators.

J Am Coll Cardiol. 2010 Jun 8;55(23):2536-43. doi: 10.1016/j.jacc.2010.03.020. Epub 2010 Apr 22. Erratum in: J Am Coll Cardiol. 2010 Jul 13;56(3):243.

9.

[Procedural success and 10-month outcome between Cypher and TAXUS drug-eluting stents for the treatment of in-stent restenosis].

Chen JL, Yang YJ, Qiao SB, Yao M, Qin XW, Xu B, Liu HB, Wu YJ, Yuan JQ, Chen J, You SJ, Dai J, Li JJ, Gao RL.

Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Apr;35(4):305-7. Chinese.

PMID:
17711652
10.

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.

11.

Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.

Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A.

Circulation. 2006 May 16;113(19):2293-300. Epub 2006 May 8.

12.

Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.

Kim YH, Park SW, Lee CW, Hong MK, Gwon HC, Jang Y, Lee MM, Koo BK, Oh DJ, Seung KB, Tahk SJ, Yoon J, Park SJ.

Catheter Cardiovasc Interv. 2006 Feb;67(2):181-7.

PMID:
16400663
13.

Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial.

Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L.

Am J Cardiol. 2009 Feb 1;103(3):345-9. doi: 10.1016/j.amjcard.2008.09.084. Epub 2008 Nov 12.

PMID:
19166687
14.

Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.

Chen J, Li JJ, Chen JL, Qiao SB, Xu B, Yang YJ, Gao RL, Qin XW, Yuan JQ, Yao M, Wu YJ, Liu HB, Dai J, You SJ.

Coron Artery Dis. 2008 Nov;19(7):507-11. doi: 10.1097/MCA.0b013e32830936d4.

PMID:
18923247
15.

Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.

Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffrè G, Prati F, Tamburino C, Ribichini F.

Diabetes Care. 2008 Jan;31(1):15-9. Epub 2007 Oct 1.

PMID:
17909090
16.

Long-term vascular changes after drug-eluting stent implantation assessed by serial volumetric intravascular ultrasound analysis.

Kang SJ, Park DW, Mintz GS, Lee SW, Kim YH, Lee CW, Han KH, Kim JJ, Park SW, Park SJ.

Am J Cardiol. 2010 May 15;105(10):1402-8. doi: 10.1016/j.amjcard.2009.12.064. Epub 2010 Apr 8.

PMID:
20451685
17.

A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati A.

Eur Heart J. 2009 Apr;30(8):923-31. doi: 10.1093/eurheartj/ehp044. Epub 2009 Feb 24.

PMID:
19240066
18.

Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.

Takasawa Y, Iijima R, Shiba M, Nakamura M, Sugi K.

J Cardiol. 2010 May;55(3):391-6. doi: 10.1016/j.jjcc.2010.01.003. Epub 2010 Feb 7.

19.

Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.

Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.

Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x.

PMID:
22954234
20.

Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.

Doi H, Maehara A, Mintz GS, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Weissman NJ, Turco MA, Ormiston JA, Stone GW.

JACC Cardiovasc Interv. 2009 Dec;2(12):1269-75. doi: 10.1016/j.jcin.2009.10.005.

Supplemental Content

Support Center